Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Recommendation of “Hold” by Brokerages

Inspire Medical Systems, Inc. (NYSE:INSP) has received a consensus recommendation of “Hold” from the nineteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $108.9412.

Several equities analysts have commented on the company. Stifel Nicolaus set a $95.00 price objective on Inspire Medical Systems in a research report on Thursday, February 12th. Royal Bank Of Canada cut their price target on shares of Inspire Medical Systems from $90.00 to $68.00 and set a “sector perform” rating on the stock in a report on Thursday, February 12th. Robert W. Baird set a $74.00 price target on shares of Inspire Medical Systems and gave the stock a “neutral” rating in a research note on Thursday, February 12th. Jefferies Financial Group lowered their price objective on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating for the company in a research report on Thursday, February 12th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, November 4th.

Inspire Medical Systems Trading Up 1.2%

Shares of NYSE:INSP opened at $60.45 on Wednesday. Inspire Medical Systems has a 12 month low of $53.11 and a 12 month high of $197.75. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 12.14, a PEG ratio of 2.98 and a beta of 0.74. The firm’s 50-day moving average is $89.59 and its 200 day moving average is $89.51.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.96. The business had revenue of $269.08 million during the quarter, compared to analyst estimates of $264.02 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.15 earnings per share. As a group, equities analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of Inspire Medical Systems stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares of the company’s stock, valued at $3,320,344.08. The trade was a 7.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Institutional investors have recently made changes to their positions in the company. Manning & Napier Advisors LLC purchased a new stake in Inspire Medical Systems in the third quarter worth about $32,000. CWM LLC raised its holdings in shares of Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after purchasing an additional 242 shares in the last quarter. Havemeyer Place LP purchased a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $39,000. V Square Quantitative Management LLC purchased a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $40,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after purchasing an additional 205 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.